… Using the example of prostate cancer, it is our hypothesis that a dynamic staging … disease
as a series of states from diagnosis to death. For an individual, progression to a different state …

… We also discuss advances in noncastrate disease states, identification of biomarkers for
prognosis and treatment selection, and opportunities in locoregional therapy to delay androgen …

… disease management along with oncological and HRQOL outcomes the Cancer of the Prostate
… in 1995 as a disease registry of men with all stages of prostate cancer. In this study we …

… recommendations for prostate cancer clinical disease states with … disease states recommended
by PCWG2 includes 5 clinical subtypes in prostate cancer based on location of disease: …

… hormonal therapy causing some men with metastatic disease to have a true increase in …
disease among some prostate cancer patients treated with hormonal therapies for early disease …

… Their disease state at the time … prostate cancer clinical disease states: locoregional,
metastatic noncastrate, and metastatic castration resistant. Locoregional disease indicates disease …

… To identify patient populations most in need of treatment across the prostate cancer
disease continuum, we developed a novel dynamic transition model based on risk of …

… For our analysis of factors affecting HRQoL across different disease states and different
instruments, we developed two linear multiple regression models: one for local …

… registries throughout the United States and Canada that participate in … , cancer site, age,
and race, but for this project, they were also developed for prostate cancer by stage of disease …

… treatment of prostate cancer. Recent reports of long-term prostate cancer outcomes stratified
… that important aspects of the biology of prostate cancer correlate with commonly available …